Dalpiciclib vs Ribociclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Dalpiciclib
Marketed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04993430 (registry estimate)
No aligned efficacy figure on record for this race.
Ribociclib
Marketed by Novartis
NCT02422615 · Phase 3 · completed
The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.
Next expected readout: November 2026 · NCT02608216 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)
Result source: NCT02422615
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dalpiciclib | Ribociclib |
|---|---|---|
| PFS, median | —Trial running · NCT06612814 | 20.5 vs 12.8+7.7 vs placeboNCT024226159 other results
|
| OS, median | —Trial running · NCT06612814 | 63.9 vs 51.4+12.5 vs placeboNCT019580211 other result
|
| ORR | —Trial running · NCT06612814 | 32.4% vs 21.5%+10.9 vs placeboNCT024226156 other results
|
| Clinical benefit rate | —Trial running · NCT06612814 | 70.2% vs 62.8%+7.4 vs placeboNCT024226154 other results
|
PFS, median
- Dalpiciclib
- —Trial running · NCT06612814
- Ribociclib
- 20.5 vs 12.8+7.7 vs placeboNCT02422615
9 other results
- 23.8 vs 13 NCT02278120
- 21.8 NCT03096847
- 8.8 NCT03096847
- 16.5 NCT03096847
- 27.6 vs 14.7 NCT03671330
- 5.3 vs 2.8 NCT02632045
- 21.8 vs 12.8 NCT03839823
- 25.1 NCT03822468
- 26.9 NCT03822468
OS, median
- Dalpiciclib
- —Trial running · NCT06612814
- Ribociclib
- 63.9 vs 51.4+12.5 vs placeboNCT01958021
1 other result
- 69.2 vs 55.5 NCT03671330
ORR
- Dalpiciclib
- —Trial running · NCT06612814
- Ribociclib
- 32.4% vs 21.5%+10.9 vs placeboNCT02422615
6 other results
- 40.9% vs 29.7% NCT02278120
- 40.7% vs 27.5% NCT01958021
- 29.3% NCT02941926
- 45.3% NCT03822468
- 41.5% NCT03822468
- 66.1% vs 61.8% NCT03839823
Clinical benefit rate
- Dalpiciclib
- —Trial running · NCT06612814
- Ribociclib
- 70.2% vs 62.8%+7.4 vs placeboNCT02422615
4 other results
- 79.1% vs 69.7% NCT02278120
- 79.6% vs 72.8% NCT01958021
- 70.7% NCT02941926
- 81.3% vs 74.5% NCT03839823
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Dalpiciclib: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dalpiciclib: 0 of 4 rows · Ribociclib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ribociclib |
|---|---|
| Dropout rate | n/a: no completion milestoneRibociclib + Fulvestranta NCT02422615 · Phase 3 · combination show 27 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestoneRibociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 59.9% NCT02941926 · Phase 3 · combination 68.7%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 76.9%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 87.9%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePostmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePremenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestone600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence n/a: no completion milestone400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 68.8%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 3.2% NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 10.5%Ribociclib + Fulvestranta NCT02422615 · Phase 3 · combination show 27 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination 4.8%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 11.4%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 15.5% NCT02941926 · Phase 3 · combination 22.6%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 23.1%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 17.8%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 11.8%PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence 6.5%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 1.3%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 12.8%600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence 11.2%400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence — NCT03477396 · Phase 2 · registry result, not featured evidence · combination 7.1%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence — NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | —Ribociclib + Fulvestranta NCT02422615 · Phase 3 · combination show 27 more results37.1%Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 24.2%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 25%Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 32.3%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT02941926 · Phase 3 · combination 30.4%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination 27.3%Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 19.2%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 28.7%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination —PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 29.4%PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence 0%PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 27.3%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 17.7%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 19.7%600mg NCT03822468 · Phase 2 · registry result, not featured evidence —400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 20.2%400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 15.2%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 6.7% NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a neutropenia 57.8% (placebo 2.5%) nausea 46.8% (placebo 31.1%) diarrhoea 34% (placebo 22.4%) NCT02422615 · Phase 3 · combination show 18 more resultsneutropenia 57.9% (placebo 6.5%) arthralgia 38.8% (placebo 36.2%) neutrophil count decreased 35.5% (placebo 1.5%) NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 nausea 75% (placebo 32.1%) anaemia 50% (placebo 7.3%) diarrhoea 50% (placebo 26.7%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 65.3% (placebo 5.5%) nausea 54.8% (placebo 32.1%) fatigue 43.4% (placebo 36.1%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 50.8% nausea 40.8% fatigue 38.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 48.1% nausea 42.1% fatigue 40.4% NCT03096847 · Phase 3 · registry result, not featured evidence · combination fatigue 57.7% neutropenia 57.7% hot flush 42.3% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 46.5% nausea 43.3% fatigue 37.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 100% (placebo 23.4%) white blood cell count decreased 100% (placebo 33.8%) anaemia 94.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence aspartate aminotransferase increased 12.5% (placebo 40.3%) blood alkaline phosphatase increased 6.3% (placebo 27.3%) blood cholesterol increased 6.3% (placebo 16.9%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 85.7% (placebo 23.4%) white blood cell count decreased 80.5% (placebo 33.8%) anaemia 48.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) blood bilirubin increased 1.4% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 88.6% (placebo 23.4%) white blood cell count decreased 87.3% (placebo 33.8%) anaemia 55.7% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 2.7% (placebo 23.4%) alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) NCT03671330 · Phase 2 · registry result, not featured evidence 600mg neutropenia 66.5% leukopenia 27.7% anaemia 26.1% NCT03822468 · Phase 2 · registry result, not featured evidence 400mg neutropenia 53.2% alanine aminotransferase increased 26.1% aspartate aminotransferase increased 21.8% NCT03822468 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 600 mg neutropenia 65.2% anaemia 35.7% leukopenia 25.9% NCT03839823 · Phase 2 · registry result, not featured evidence neutropenia 71.7% (placebo 15.3%) fatigue 33.3% (placebo 32.2%) aspartate aminotransferase increased 25% (placebo 28.8%) NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ribociclib
show 7 more results
show 5 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
show 2 more results
+ 50 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalpiciclib's landscape · Ribociclib's landscape